Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allergic conditions

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    78 result(s) found for: Allergic conditions. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2007-003403-13 Sponsor Protocol Number: CQAX576A2104 Start Date*: 2007-12-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A proof of concept study of the effects of QAX576 (an interleukin-13 monoclonal antibody) on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with...
    Medical condition: Seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005340-12 Sponsor Protocol Number: IPR101987 Start Date*: 2006-03-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 14 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in an environmental exposition unit (Vienna Challenge Chamber) in ...
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039776 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003096-35 Sponsor Protocol Number: WF10-C-2013/R-2-02 Start Date*: 2014-01-10
    Sponsor Name:Nuvo Research GmbH
    Full Title: A multi-centre, randomised, placebo-controlled, double-blind, parallel-group study on the efficacy and safety of WF10 and its main constituents in patients with refractory allergic rhinitis
    Medical condition: refractory allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004255-10 Sponsor Protocol Number: 6078-PG-PSC-164 Start Date*: 2007-11-12
    Sponsor Name:LETI Pharma GmbH
    Full Title: Randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Depigoid® Grass Mix in patients with al-lergic rhinitis and/or rhinoconjunctivitis with or ...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis with or without mild intermitent asthma caused by clinical relevant sensitization against grass pollen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013429-40 Sponsor Protocol Number: CVAK694A2205 Start Date*: 2009-10-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, double-blind, placebo-controlled trial to determine the capacity of VAK694 to elicit long term immune tolerance when combined with subcutaneous allergen immunotherapy for the treatment ...
    Medical condition: Seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004092-22 Sponsor Protocol Number: HH3110163 Start Date*: 2008-09-03
    Sponsor Name:GlaxSmithKline Research & Development Limited
    Full Title: A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy a...
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001567-10 Sponsor Protocol Number: HHI110159 Start Date*: 2008-06-25
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, double-blind, placebo-controlled, 3-period crossover study to assess the efficacy and safety of single dose intranasal GSK1004723 compared with placebo in an allergen challenge chambe...
    Medical condition: seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006648-23 Sponsor Protocol Number: CIGE025A2437 Start Date*: 2008-11-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis
    Medical condition: Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    9.1 10000244 ABPA LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) IE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022113-25 Sponsor Protocol Number: RVH002 Start Date*: 2010-10-20
    Sponsor Name:RespiVert Ltd
    Full Title: A two day, randomised, single blind, parallel group trial of repeat doses of intranasal RV568 in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001584-66 Sponsor Protocol Number: 1301-PG-PSC-136 Start Date*: 2005-08-29
    Sponsor Name:LETI Pharma GmbH
    Full Title: A randomised controlled multicentre study for the safety of Depigoid(R) rush schedule
    Medical condition: Rhinitis and/or rhinoconjunctivitis without uncontrolled asthma caused by clinical relevant sensitisation againts tree pollen, grass pollen or house dust mites
    Disease: Version SOC Term Classification Code Term Level
    8.0 10001723 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011459-39 Sponsor Protocol Number: HHI112864 Start Date*: 2009-05-28
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled 4-period crossover study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000μg), oral GSK835726 (10mg) and cetirizine (10mg) ...
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002708-13 Sponsor Protocol Number: SP002 Start Date*: 2004-12-27
    Sponsor Name:Synergia Pharma, Inc.
    Full Title: A RANDOMIZED, BLINDED, CROSSOVER TRIAL OF A SINGLE DOSE OF ORAL L-DOPS 300 MG IN AN ENVIRONMENTAL EXPOSURE UNIT IN SUBJECTS WITH SEASONAL ALLERGIC RHINITIS
    Medical condition: seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10039776 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000115-11 Sponsor Protocol Number: VR1111924 Start Date*: 2011-04-19
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A randomized, double-blind, placebo controlled, incomplete block, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of SB-705498 when adminis...
    Medical condition: Allergic rhinitis.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003715-22 Sponsor Protocol Number: DMV01-SIT-015 Start Date*: 2020-11-04
    Sponsor Name:Inmunotek, S.L.
    Full Title: Prospective, randomized, placebo-controlled, multi-center trial comparing the efficacy and safety of subcutaneous immunotherapy with a mixture of grasses and mites at adequate doses versus monother...
    Medical condition: Mild to moderate asthma and allergic rhinitis / rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    20.0 100000004870 10020419 House dust mite allergy LLT
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000684-10 Sponsor Protocol Number: ME3301-12 Start Date*: 2004-10-28
    Sponsor Name:Meiji Seika Kaisha, Ltd.
    Full Title: A randomised, double-blind, placebo-controlled crossover study to investigate the efficacy and safety of three doses of ME3301 in patients with seasonal allergic rhinitis during allergen challenge ...
    Medical condition: seasonal allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002478-47 Sponsor Protocol Number: FG-506-06-FR-05 Start Date*: 2005-04-06
    Sponsor Name:Fujisawa GmbH
    Full Title: Comparative, multicentre, randomised, double-blind study to assess the efficacy of tacrolimus 0.03% ointment versus fluticasone 0.005% ointment in children aged 2 years or over suffering from moder...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10003639 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002223-25 Sponsor Protocol Number: NL60891.091.17 Start Date*: 2018-05-25
    Sponsor Name:Radboud University Medical Center
    Full Title: Pilot study on the effect of prophylactic versus therapeutic treatment with coal tar and vaseline lanette ointment on the skin barrier repair mechanisms in absence of a chronic inflammatory compone...
    Medical condition: Atopic dermatits
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    20.0 100000004858 10003640 Atopic dermatitis and related conditions LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017407-28 Sponsor Protocol Number: H 527 000-0917 Start Date*: 2010-01-27
    Sponsor Name:Almirall Hermal GmbH
    Full Title: A phase II, single-center, randomized, controlled, double-blind study to assess effects on skin conditions and patient reported outcome of a topical formulation containing LAS41002 on lesional skin...
    Medical condition: Clinical condition of atopic eczema mild to moderate defined by a local SCORAD of at least 5 with • erythma ≥ 2 • lichenification ≥ 1 • dryness ≥ 1 • itching ≥ 1 • Erlangen atopy score sum equal...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003070-39 Sponsor Protocol Number: CYT003-QbG1012 Start Date*: 2012-11-26
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients with Moderate to Severe Allergic Asthma not Sufficiently Controlled on Current Standard T...
    Medical condition: Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002203-34 Sponsor Protocol Number: M16-813 Start Date*: 2021-04-28
    Sponsor Name:AbbVie Deutschland
    Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:35:12 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA